Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Acute Aortic Thrombosis Following Capecitabine Chemotherapy in a Patient with Colon Cancer

Capecitabine 항암요법 후 발생한 급성 대동맥 혈전

  • Lee, Min Kyung (Department of Radiology, Gachon University Gil Medical Center) ;
  • Kim, Eun Young (Department of Radiology, Gachon University Gil Medical Center) ;
  • Kim, Young Saing (Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Sym, Sun Jin (Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Kim, Jeong Ho (Department of Radiology, Gachon University Gil Medical Center)
  • 이민경 (가천대학교 길병원 영상의학과) ;
  • 김은영 (가천대학교 길병원 영상의학과) ;
  • 김영생 (가천대학교 길병원 내과) ;
  • 심선진 (가천대학교 길병원 내과) ;
  • 김정호 (가천대학교 길병원 영상의학과)
  • Received : 2018.01.31
  • Accepted : 2018.05.01
  • Published : 2018.09.01
⟨ Previous Next ⟩

Abstract

The elevated risk for thromboembolic events in cancer patients has been well documented. Chemotherapy is considered to be one of the most important risk factors for cardiovascular complications such as arrhythmias, cardiomyopathy, angina, and myocardial infarction. However, acute aortic thrombosis is an extremely rare complication in patients receiving chemotherapy. The authors report a case of acute aortic thrombosis after adjuvant capecitabine chemotherapy for colon cancer.

암 환자에서 혈전 색전증의 위험이 증가하며, 항암 화학 치료는 심혈관 합병증(부정맥, 심근증, 협심증, 심근경색 등)의 중요한 위험 요인 중 하나이다. 급성 대동맥 혈전증은 항암 화학 요법을 받고 있는 암 환자에게 극히 드물게 나타나는 합병증이다. 저자는 대장암에 대한 보조 항암 화학요법으로 capecitabine 경구 치료 중 급성 대동맥 혈전증이 발생한 경우를 보고한다.

Keywords

References

  1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815 https://doi.org/10.1001/archinte.160.6.809
  2. Doganci S, Kadan M, Kaya E, Erol G, Gunay C, Demirkilic U. Acute arterial thrombosis following chemotherapy in a patient with a gastric carcinoma. Cardiovasc J Afr 2013;24:e7-e9
  3. Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract 2016;22:454-460 https://doi.org/10.1177/1078155215587345
  4. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 2012;19:453-458 https://doi.org/10.5603/CJ.2012.0084
  5. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 2011;9:120-138
  6. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127-3139 https://doi.org/10.1016/j.ejca.2006.09.015
  7. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239 https://doi.org/10.1093/jnci/djm086
  8. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995;9:561-576
  9. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl):234S-264S https://doi.org/10.1378/chest.126.3_suppl.234S
  10. Tait CD, Rankin EM. Arterial emboli complicating cisplatin therapy. Case Rep Oncol Med 2012;2012:276385